|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG005900212 |
| 003 |
DE-627 |
| 005 |
20230425165209.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2012 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG005900212
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2005-001340-22-GB
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)BHT-3009-03
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS
|b BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 18-07-2005, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2012) vom: 24. Apr.
|
| 773 |
1 |
8 |
|g year:2012
|g day:24
|g month:04
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001340-22
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2012
|b 24
|c 04
|
Klinische Studie